Patents Issued in January 3, 2019
-
Publication number: 20190002551Abstract: The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of immunobinders, and in particular of single chain antibodies (scFvs), including such properties as stability, solubility, and/or antigen binding affinity. The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions at amino acid positions identified by analysis of a database of selected, stable scFv sequences, wherein preferred amino acid residues for substitution have been identified. The invention also provides immunobinders prepared according to the engineering methods of the invention. The invention also provides preferred scFv framework scaffolds, into which CDR sequences can be inserted, as well as scFv antibodies made using these preferred framework scaffolds.Type: ApplicationFiled: September 12, 2017Publication date: January 3, 2019Inventors: David Urech, Leonardo Borras
-
Publication number: 20190002552Abstract: Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations.Type: ApplicationFiled: June 7, 2018Publication date: January 3, 2019Inventors: Ajay DESHMUKH, Joumana ZEID, Thomas M. SCHERER
-
Publication number: 20190002553Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 21, 2018Publication date: January 3, 2019Applicants: Singapore Health Services PTE LTD., National University of SingapoInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20190002554Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: ApplicationFiled: September 13, 2018Publication date: January 3, 2019Inventors: Hermann Gram, Thomas Jung
-
Publication number: 20190002555Abstract: The present invention provides monoclonal antigen-binding proteins that bind to the cardiac glycoside marinobufagenin (MBG), and methods of use. In various embodiments of the invention, the antigen-binding proteins are fully human antigen-binding proteins that bind to MBG. In some embodiments, the antigen-binding proteins of the invention are useful for inhibiting or neutralizing MBG activity, thus providing a means of treating or preventing a MBG-associated disease or disorder selected from the group consisting of hypertension, myocardial fibrosis, uremic cardiomyopathy, heart failure, myocardial infarction, renal failure, renal fibrosis and pre-eclampsia.Type: ApplicationFiled: July 21, 2016Publication date: January 3, 2019Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Michael E. DUNN, Lori C. MORTON, Yonaton RAY, Jee H. KIM
-
Publication number: 20190002556Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.Type: ApplicationFiled: June 29, 2018Publication date: January 3, 2019Inventors: Claudia WAGNER, Leonie ALTEN, Sebastian BUNK, Dominik MAURER
-
Publication number: 20190002557Abstract: The disclosure relates to compositions and methods of mitigating tissue damage and fibrosis in a patient by modulating latent transforming growth factor beta binding protein (LTBP4)-induced proteolysis of a TGF? superfamily protein.Type: ApplicationFiled: September 5, 2018Publication date: January 3, 2019Inventors: Elizabeth McNally, Ahlke Heydemann, Ermelinda Ceco
-
Publication number: 20190002558Abstract: Disclosed are methods of identifying binding moieties that recognize antigens displayed on cells, such as membrane proteins or recombinant proteins that display eptiopes on the surface of cells. Binding moieties capable of binding membrane proteins can be difficult to obtain because these proteins can depend on their native environments for structural integrity. In some methods scFv phage display libraries are panned against whole cells expressing a membrane protein in an emulsion. Certain methods further permit discrimination of binding moieties according to their affinity or avidity for a target. This approach allows rapid identification of cell surface epitope specific antibodies for research, diagnostics, and immunotherapeutics.Type: ApplicationFiled: June 1, 2018Publication date: January 3, 2019Inventors: Michael WEINER, Margaret KISS
-
Publication number: 20190002559Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: ApplicationFiled: September 7, 2018Publication date: January 3, 2019Applicant: RINAT NEUROSCIENCE CORP.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Publication number: 20190002560Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 11, 2016Publication date: January 3, 2019Applicant: ALECTOR LLCInventors: Kate MONROE, Helen LAM, Francesca AVOGADRI-CONNORS, Seung-Joo LEE, William MONTEITH, Herve RHINN, Arnon ROSENTHAL
-
Publication number: 20190002561Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD33 monoclonal antibody, conferring specific immunity against CD33 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.Type: ApplicationFiled: March 20, 2018Publication date: January 3, 2019Inventor: Roman GALETTO
-
Publication number: 20190002562Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.Type: ApplicationFiled: September 13, 2018Publication date: January 3, 2019Applicant: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
-
Publication number: 20190002563Abstract: The present invention is directed to B7-H3×CD3 bispecific monovalent diabodies, and particularly, to B7-H3×CD3 bispecific monovalent Fc diabodies, that are capable of simultaneous binding to B7-H3 and CD3. The invention is also directed to pharmaceutical compositions that contain such bispecific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.Type: ApplicationFiled: August 12, 2016Publication date: January 3, 2019Applicant: MacroGenics, Inc.Inventors: Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Ling Huang, Kalpana Shah, Ralph Alderson, Gurunadh Reddy Chichili
-
Publication number: 20190002564Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: September 18, 2018Publication date: January 3, 2019Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20190002565Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: September 18, 2018Publication date: January 3, 2019Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20190002566Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.Type: ApplicationFiled: September 19, 2018Publication date: January 3, 2019Inventors: Bruce Alan Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
-
Publication number: 20190002567Abstract: Disclosed is an anti-CD303 protein antibody for use in the prophylaxis or therapy of a tumor, involving plasmacytoid dendritic cell activation in the environment of the tumor, said plasmacytoid dendritic cells not being the cause of the tumor.Type: ApplicationFiled: December 16, 2016Publication date: January 3, 2019Inventors: Abdessatar Sami CHTOUROU, Nathalie FOURNIER
-
Publication number: 20190002568Abstract: Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.Type: ApplicationFiled: July 11, 2018Publication date: January 3, 2019Inventors: Luis G. Borges, Patrick Bauerle, Wei Yan, Mark L. Michaels
-
Publication number: 20190002569Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.Type: ApplicationFiled: September 4, 2018Publication date: January 3, 2019Inventors: Zakia Belaid-Choucair, Olivier Hermine, Carmen Garrido-Fleury, Claude Cochet, Odile Filhol-Cochet, Renaud Seigneuric
-
Publication number: 20190002570Abstract: Herein is reported a method for producing a bispecific antibody comprising the step of incubating (i) an antibody Fab fragment or a scFv antibody comprising within the 20 C-terminal amino acid residues the amino acid sequence LPX1TG (SEQ ID NO: 01), (ii) a one-armed antibody comprising a full length antibody heavy chain, a full length antibody light chain, and an Fc-heavy chain, whereby the full length antibody heavy chain and the full length antibody light chain are cognate antibody chains that thereof forms an antigen binding site, whereby the full length antibody heavy chain and the Fc-heavy chain are covalently linked to each other via one or more disulfide bonds forming an antibody hinge region, and whereby the Fc-heavy chain has an oligoglycine amino acid sequence at its N-terminus, and (iii) a Sortase A enzyme.Type: ApplicationFiled: September 17, 2018Publication date: January 3, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Sebastian FENN, Erhard KOPETZKI, Georg TIEFENTHALER
-
Publication number: 20190002571Abstract: Methods for the therapeutic use of competitive inhibitors of the CCR5/CCL5 axis that express antagonist activity for RANTES (CCL5) for immunomodulatory treatment of subjects in need thereof. The competitive inhibitors may not have CCL5 agonist activity and can be used to inhibit, interrupt, block, mitigate, slow the progress of, and/or treat inflammation and/or various other CCR5/CCL5 axis signaling dependent down-stream activities associated with transplantation, including graft versus host disease, autoimmune disorders, infectious agents, chronic inflammation, and cancer, etc.Type: ApplicationFiled: June 23, 2016Publication date: January 3, 2019Inventor: Denis R. Burger
-
Publication number: 20190002572Abstract: A preventive and/or therapeutic agent for systemic lupus erythematosus comprising an anti-interleukin-6 (IL-6) receptor antibody as an active ingredient.Type: ApplicationFiled: January 26, 2018Publication date: January 3, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Masahiko Mihara, Yoshiyuki Ohsugi
-
Publication number: 20190002573Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.Type: ApplicationFiled: March 19, 2018Publication date: January 3, 2019Inventor: Roman GALETTO
-
Publication number: 20190002574Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.Type: ApplicationFiled: August 9, 2018Publication date: January 3, 2019Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
-
Publication number: 20190002575Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.Type: ApplicationFiled: September 17, 2018Publication date: January 3, 2019Inventors: Roland Martin, Henry McFarland, Bibiana Bielekova
-
Publication number: 20190002576Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: ApplicationFiled: September 19, 2018Publication date: January 3, 2019Applicant: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, John Dixon Gray
-
Publication number: 20190002577Abstract: The present invention relates to methods of treating Type 2 diabetes (T2D), comprising administering to a patient an effective amount of an isolated antagonistic antigen binding protein that specifically binds to the human glucagon receptor, either as monotherapy, or in combination with one or more antidiabetic medications.Type: ApplicationFiled: January 4, 2017Publication date: January 3, 2019Applicant: REMD Biotherapeutics, Inc.Inventors: Jim Shi, Hai Yan
-
Publication number: 20190002578Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.Type: ApplicationFiled: July 2, 2018Publication date: January 3, 2019Inventors: Lewis Lee Brayshaw, Michael Menteith Hann, Christopher Herring, Carlos Martinez Fleites, Markus Alexander Queisser
-
Publication number: 20190002579Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.Type: ApplicationFiled: April 25, 2018Publication date: January 3, 2019Inventors: George GEORGIOU, Everett STONE, Nicholas MARSHALL, John BLAZECK, Wei-Cheng LU
-
Publication number: 20190002580Abstract: The present invention relates to immunology, biotechnology and medicine, notably to the field of antitumor pharmaceuticals based on monoclonal antibodies, and can be used in medicine for the treatment of oncological diseases. The object of the invention was to create an efficient and safe universal antitumor agent, the production of which effective, quick and easy. This problem is solved by the proposed humanized monoclonal antibody specific to syndecan-1, of the IgG4 isotype, or with IgG3 fragments and amino acid substitutions for the increase the antibody half-life, characterized by a definite combination of the calculated and created by the authors amino acid and nucleotide sequences, which is used as a self-acting substance for the therapy of tumor diseases. Nucleotide sequences additionally contain a fragment coding for a signal secretory sequence at the N-terminus, and are codon-optimized to increase antibody production in mammalian cells.Type: ApplicationFiled: July 21, 2016Publication date: January 3, 2019Inventors: Ilya Vladimirovich DUKHOVLINOV, Anton Iosifovich ORLOV, Mark Borisovich BALAZOVSKIY
-
Publication number: 20190002581Abstract: Provided herein are antibodies that selectively bind to EpCAM and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.Type: ApplicationFiled: July 28, 2016Publication date: January 3, 2019Inventors: Ryan Stafford, Alice Yam, John Lee, Stephanie Armstrong, Aaron Sato
-
Publication number: 20190002582Abstract: The present invention relates to methods for the in vitro diagnosis of ovarian cancer, and to compositions and methods for the prevention or the treatment of ovarian cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.Type: ApplicationFiled: January 2, 2017Publication date: January 3, 2019Applicant: Progastrine et Cancers S.À R.L.Inventor: Alexandre Prieur
-
Publication number: 20190002583Abstract: A combination which comprises an effective amount of Her2/Neu antagonist and an effective amount of immunotherapeutic that is capable of activating a human plasmacytoid dendritic cell, myeloid dendritic cell, NK cell, or a combination thereof is disclosed.Type: ApplicationFiled: January 6, 2017Publication date: January 3, 2019Inventor: Lixin Li
-
Publication number: 20190002584Abstract: Disclosed herein are anti-Factor Xlla antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.Type: ApplicationFiled: July 21, 2016Publication date: January 3, 2019Applicant: Dyax Corp.Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
-
Publication number: 20190002585Abstract: Provided herein are compositions, systems, kits, and methods for treating cancer by administering to a subject a first agent selected from: a PDE12 inhibiting agent, a AKAP7 inhibiting agent, an ADAR1 inhibiting agent, and/or a RNase L enhancer, and a second agent that comprises a DNA methylation inhibiting agent (e.g., a DNA methyltransferase demethylase inhibitor).Type: ApplicationFiled: June 7, 2018Publication date: January 3, 2019Inventors: Robert H. Silverman, Shuvojit Banerjee
-
Publication number: 20190002586Abstract: Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.Type: ApplicationFiled: September 7, 2018Publication date: January 3, 2019Applicant: BROWN UNIVERSITYInventors: Jack A. ELIAS, Chun Geun LEE, Chuan Hua HE, Bing MA, Suchitra KAMLE, Chang-Min LEE
-
Publication number: 20190002587Abstract: The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments.Type: ApplicationFiled: September 14, 2018Publication date: January 3, 2019Inventor: Staffan ERIKSSON
-
Publication number: 20190002588Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.Type: ApplicationFiled: January 11, 2017Publication date: January 3, 2019Inventors: Toshinori Nakayama, Motoko Kimura, Koji Hayashizaki, Toshifumi Hirayama, Jungo Kakuta, Yoshimasa Sakamoto, Ryu Gejima, Daisuke Tokita, Kenzo Muramoto, Toshio Imai
-
Publication number: 20190002589Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.Type: ApplicationFiled: June 11, 2018Publication date: January 3, 2019Applicant: NOVARTIS AGInventors: Michael Otto BARDROFF, Tina BUCH, Christian GRAF, Daniel HEITMANN, Thomas JOSTOCK, Hans-Peter KNOPF, Rolf KOEHLER, Jiri KOVARIK, Stephen John OLIVER, Dhavalkumar PATEL, Maximilian WOISETSCHLAEGER
-
Publication number: 20190002590Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: ApplicationFiled: December 2, 2016Publication date: January 3, 2019Applicant: Fred Hutchinson Cancer Research CenterInventors: Philip Bradley, Barry L. Stoddard
-
Publication number: 20190002591Abstract: A process for the preparation of particulate acylated biopolymer comprising anhydroglucose units that comprises several steps. First, dispersing an amount of particulate non-surface modified biopolymer comprising anhydroglucose units in an amount of a liquid alkenyl carboxylatein order to form a first dispersion. Then, adding a catalytic composition to the first dispersion such a to form a second dispersion, heating the second dispersion to a temperature above ambient temperature, and cooling the second dispersion to ambient temperature. Thereafter, the obtained particulate acylated biopolymer is isolated. The amount of a liquid alkenyl carboxylate corresponds to a molar excess of alkenyl carboxylate, the molar excess being defined with respect to the moles of anhydroglucose units comprised in the amount of the particulate non-surface modified biopolymer. The catalytic composition comprises an amount of one, or two or more, non-nucleophilic bases.Type: ApplicationFiled: December 19, 2016Publication date: January 3, 2019Applicant: SAPPI Netherlands Services B.V.Inventors: Robert ENGLISH, Ian GRAVESON, Saschi MOMIN, Nadege FERLIN
-
Publication number: 20190002592Abstract: A process for treating crop kernels is comprised of the steps of a) soaking kernels in water to produce soaked kernels; b) grinding the soaked kernels; c) treating the soaked kernels in the presence of an effective amount of GH62 polypeptide having arabinofuranosidase activity or a GH43 polypeptide having arabinofuranosidase activity, wherein step c) is performed before, during or after step b).Type: ApplicationFiled: November 25, 2016Publication date: January 3, 2019Applicant: Novozymes A/SInventors: Yi Cao, James Lavigne, Bernardo Vidal, Jr., Thomas Patrick Gibbons, Chee-Leong Soong, Brian R. Scott, Randall Scott Deinhammer, Zhen Long, Michael John Akerman, Xinyu Shen, Yu Zhang
-
Publication number: 20190002593Abstract: Process for the production of thermally modified starch comprising the steps of mixing starch in powder form having a specific moisture content with an alkaline water solution to obtain a wet powder; feeding a continuous flow of said wet powder into a continuous dryer together with a continuous flow of hot air; discharging a continuous flow of dried powder from said continuous drier; supplying said continuous flow of said dried powder into a turbo-reactor, in which the inner wall of said turbo-reactor is maintained at a specific temperature; converting said dried powder into a thermally inhibited starch; and discharging said thermally inhibited starch from said turbo-reactor; it is also disclosed a thermally inhibited starch obtained from the aforementioned process with enhanced physical chemical properties.Type: ApplicationFiled: June 27, 2018Publication date: January 3, 2019Applicant: Ambiente E Nutrizione S.R.L.Inventor: Massimo Vezzani
-
Publication number: 20190002594Abstract: The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.Type: ApplicationFiled: July 5, 2018Publication date: January 3, 2019Inventors: Tomas Hode, Robert E. Nordquist, Wei R. Chen, Raoul Carubelli, Luciano Alleruzzo, Peter Jenkins, Kristopher Waynant, Joseph Raker
-
Publication number: 20190002595Abstract: Provided is a technique for enhancing the absorption of fucoidan into the body and elevate various effects of fucoidan by using a fucoidan preparation that is characterized by containing fucoidan and zinc and the ratio of zinc to fucoidan being 0.005% or greater.Type: ApplicationFiled: December 11, 2015Publication date: January 3, 2019Applicant: South Product Ltd.Inventors: Takeaki NAGAMINE, Masahiko IHA, Kizuku KADENA
-
Publication number: 20190002596Abstract: Provided are a sulfated heparin oligosaccharide as well as a preparation method and an application thereof. The sulfated heparin oligosaccharide molecule contains an unsaturated double bond resulting from enzymolysis by heparinase at the non-reducing end thereof, an uronic acid derivative and a glycosylamine derivative; and has a structure represented by formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, Ra, Rb, Rc, Rd; Rx?, Ry?, Rz?, and n are as defined herein. The preparation method obtains a sulfated oligosaccharide with a controllable degree of sulfation. The sulfated heparin oligosaccharide has a high activity for inhibiting heparanase in vitro, with an activity 4-5 times higher than that of heparin for inhibiting cell adhesion and migration, and an activity 2-3 times higher than that of heparin for resisting tumor metastasis in mice, thus having a relatively good effect in resisting tumor metastasis and a relatively high specificity.Type: ApplicationFiled: December 30, 2015Publication date: January 3, 2019Applicant: SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.Inventor: Li LI
-
Publication number: 20190002597Abstract: A process for epoxidation of an unsaturated polymer involves mixing an unsaturated polymer and a peroxy acid in an absence of solvent to produce an epoxidized polymer. The process may require no solvent, require no catalyst, require no or little applied external heat input, require no applied cooling, require less epoxidation agent, be faster and/or result in more efficient conversion of the unsaturated polymer.Type: ApplicationFiled: December 14, 2016Publication date: January 3, 2019Applicant: ARLANXEO Singapore Pte. Ltd.Inventors: Brianna BINDER, Sarah ELLIOTT, Gregory J.E. DAVIDSON, Sharon GUO
-
Publication number: 20190002598Abstract: The present invention provides an azasilane-based modifier of Formula 1, which may easily introduce a functional group having affinity with a filler into a conjugated diene-based polymer chain, a modified and conjugated diene-based polymer including the functional group derived from the azasilane-based modifier, a method for preparing the modified and conjugated diene-based polymer, a rubber composition including the modified and conjugated diene-based polymer, and a molded article and a tire manufactured from the rubber composition.Type: ApplicationFiled: February 24, 2017Publication date: January 3, 2019Applicant: LG Chem, Ltd.Inventors: Ho Young Lee, No Ma Kim, Sang Mi Lee, Da Won Chai
-
Publication number: 20190002599Abstract: A tire comprising a rubber composition comprising a substituted diene elastomer is provided. The substituted diene elastomer comprises units bearing an A-B radical, in which: A represents an aliphatic C3-C35 radical which can be interrupted by one or more heteroatom(s), and B represents a linear, branched or cyclic C1-C6 hydrocarbon radical. A and B are such that the melting point of the analogue, H-A-B, is less than 70° C., and the substituted diene elastomer comprises from 10% to 40% by weight of the A-B radical, with respect to the total weight of the elastomer. A tread comprising such a rubber composition is also provided. A rubber composition comprising such a substituted diene elastomer and at least one of the following constituents: a second diene elastomer; a reinforcing filler and, if appropriate, a coupling agent is also provided.Type: ApplicationFiled: December 22, 2016Publication date: January 3, 2019Applicant: COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELINInventors: Séverin DRONET, Corentin PAVAGEAU, Benoît SCHNELL
-
Publication number: 20190002600Abstract: Provided is a method of suspension polymerization comprising (I) providing a composition comprising droplets distributed in an aqueous medium, wherein the droplets comprise one or more boronic acids, one or more monomers, and one or more initiators, and wherein the aqueous medium comprises polyvinyl alcohol; wherein the one or more boronic acids are present in an amount of 0.002% or more, by weight based on the weight of the droplets, and (II) stressing the composition so that the initiator initiates polymerization of the monomer.Type: ApplicationFiled: December 15, 2016Publication date: January 3, 2019Inventors: Andrew M. Savo, Matthew D. Reichert, John David Finch, Lester H. Mcintosh, III, Robert Johnson, Alfred K. Schultz